Related Blog Posts from the Wikinvest Wire

Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part of the AWARD program. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly [...]

OncoGenex Pharmaceuticals, Inc. (OGXI) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of previously untreated advanced non-squamous non-small cell lung cancer (NSCLC). The investigator-sponsored, randomized, double-blind, placebo-controlled phase II study will evaluate whether progression-free survival (PFS) outcomes can be improved by adding [...]

Eli Lilly and Company’s (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP issued an opinion in favor of approving Eli Lilly’s erectile dysfunction (ED) drug, Cialis (5 mg), for the once-daily treatment of the signs and symptoms [...]

According to a report in BusinessWeek ,  pharmaceutical major, Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), has won its case in the U.S. Court of Appeals relating to patent protection for its compound patent, for Alimta (premetrexed). The drug curtails the tendency of cancerous cells to use folic acid and grow regardless of treatment with drugs. The ruling means [...]

Amgen (AMGN) recently suffered a pipeline setback with the company deciding to halt the development of its oncology candidate, ganitumab (AMG 479).The decision was based on the recommendation of an independent Data Monitoring Committee (DMC). The randomized, multicenter, double-blind, phase III study (GAMMA) evaluated whether the combination of AMG479 and Eli Lilly’s (LLY) Gemzar improved overall [...]

by Jay Allen  Eli Lilly (LLY) is an asset in the healthcare sector that currently presents moderate-risk or high-reward for current shareholders and interested investors. The unlikely approval of an Alzheimer’s drug from Eli Lilly has the potential to skyrocket its revenues and change the industry or leave Eli Lilly strapped for revenue income for years [...]

Three of the largest pharmaceutical companies have reported their earnings for the second quarter of 2012; GlaxoSmithKline plc (NYSE:GSK), Eli Lilly & Co. (NYSE:LLY), and Bristol Myers Squibb Co. (NYSE:BMY). GlaxoSmithKline plc (NYSE:GSK) reported an EPS of 40 cents for the quarter ending on June 30th, while diluted per share earnings were 39.7 cents, which misses the analysts' estimates. For [...]

Eli Lilly and Company (LLY) is heavily focused on expanding its portfolio and market share in the diabetes and insulin industry. Growth and earnings in the near- and long-term future are heavily centered on its ability to get products approved from its pipeline, forming productive partnerships, and responsible fiscal management on one-time expenses incurred as [...]

Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly treatment of type II diabetes. Results from the phase II, randomized, [...]

Company Background: Eli Lilly & Co (NYSE:LLY) was incorporated in 1876 and is engaged in development, manufacturing and selling of pharmaceutical products around the globe. Based in Indianapolis, Indiana, the company offers neuroscience products for the treatment of schizophrenia, manic episodes and bipolar maintenance, depression and diabetic peripheral neuropathic pain, and attention deficit hyperactivity disorder in [...]

Company Background: Eli Lilly & Co (NYSE:LLY) was incorporated in 1876 and is engaged in development, manufacturing and selling of pharmaceutical products around the globe. Based in Indianapolis, Indiana, the company offers neuroscience products for the treatment of schizophrenia, manic episodes and bipolar maintenance, depression and diabetic peripheral neuropathic pain, and attention deficit hyperactivity disorder in [...]

Stock Performance: Eli Lilly & Co. (NYSE:LLY) stock picks dropped by 1.08% to close at $41.30 with total traded volume of 3.22 million shares in the last trading session as compare to its average volume stood at 8.45 million. The company (stock picks) is in highly profitability with ROE of 33.92%. The company (stock picks) stands in [...]

Looking for yield now that the Fed has declared a 4th and 5th year of war on savers?  Well as long as your stocks stay flattish you can do far better in the stock market in yield.  Bespoke has a list of non utilities in the Russell 3000 yielding at least 4%.  Pretty amazing to see something relatively stable like LLY yielding 5.65%!  Smoking isn't going anywhere soon either - RAI for 6.4% yield? Not too bad. (please note the table is incorrectly labeled 'at least 5%' [click to enlarge]

Eli Lilly & Co. (NYSE: LLY) reported Thursday that its second quarter profit declined to $1.2 billion, or $1.07 a share, from $1.35 billion, or $1.22 a share, in the year-quarter. On an adjusted basis, the company earned $1.18 per share in the share in the latest quarter. Revenue rose 8.8% to $6.25 billion. Analysts, on average, expected earnings of $1.18 on revenue of $6.03 billion. "In the second quarter, Lilly once again achieved solid volume-driven revenue growth, despite the...

Courtesy of Benzinga Eli Lilly & Co (NYSE: LLY) reported an 11% decline in its second-quarter earnings. LLY's quarterly net income dropped to [...]

The number of stocks that made substantial gains for the week was limited. The great exception to that rule was Petrohawk Energy Corporation Co (NYSE: HK) which jumped 62.5% on Friday after a buyout bid from BHP Billiton Ltd (NYSE: BHP). Another stock...

Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products. About $7 billion of revenues will be lost to generic competition due [...]

Apple (NASDAQ:AAPL) shares have dropped 4 percent this month, capping their worst first-half performance in three years, as investors await new products and fret that rivalry from Google will slow growth. The shares, down 8 percent from a record $363.13 on Feb. 16, haven’t performed this poorly in the first six [...]

Eli Lilly and Company (LLY) and partner Boehringer Ingelheim Pharmaceuticals, Inc. recently announced that their type II diabetes treatment, Tradjenta (linagliptin) is now available in pharmacies across the US. Tradjenta, which has been priced at $6.77 per tablet, is available at Walgreen (WAG), CVS Caremark Corp. (CVS), Rite Aid Corp. (RAD) and several other leading [...]

Andrew Hawkins, Guest Editor This is part four of the Dividend Rocket series. If you missed parts 1, 2, or 3, check them out. Investment Underground took another look at some dividend rockets that are set to take off and produce great value to those holding the stocks. Take a look at 8 more companies that [...]

Dean Foods Company (NYSE:DF) reported the gain of 9.20% to close at $13.41 with overall traded volume of 14.68 million shares in the last trading day as compare to its average volume stood at 4.44 million. The company is in highly profitability with ROE of 6.07%. Aetna Inc. (NYSE:AET) closed at $43.85 after surging by 2.38% [...]

Amylin Pharmaceuticals, Inc. (AMLN) and its partners, Eli Lilly and Company (LLY), and Alkermes, Inc. (ALKS), recently received good news regarding their pipeline candidate, Bydureon (exenatide once-weekly). Amylin, Eli Lilly and Alkermes said that Bydureon received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP issued [...]

Eli Lilly & Co., (NYSE: LLY) reported that its first-quarter net income slipped 15% to $1.06 billion, or 95 cents a share, from $1.25 billion, or $1.13, in the year-earlier quarter. On an adjusted basis, the company earned $1.24 in the latest quarter. Revenue rose to $5.84 billion from $5.49 billion. Analysts, on average, expected the company to report earnings of $1.16 per share on revenue of $5.70 billion. For 2011, Lilly affirmed that it expects to earn an adjusted $4.15 to $4.30 a...

Eli Lilly & Co. (NYSE: LLY) is scheduled to release first-quarter earnings before the opening bell on Monday, April 18, 2011. Analysts, on average, expect the company to report earnings of $1.16 per share on revenue of $5.70 billion. In the year-ago period, the company reported earnings of $1.18 per share on revenue of $5.49 billion. Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. Its products are sold in approximately 125 countries. s...

Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Axiron Rights Acquired in March 2010 Eli Lilly acquired exclusive [...]

The research of Alzheimer's disease continues as new tests show great promise for the early diagnosis of the illness. According to the New York Times, the Food and Drug Administration will review a newly developed brain scan which purportedly can detect plaques indicative of Alzheimer's disease. A critical component of the brain scan is a dye created by Avid Pharmaceuticals, a company owned by Eli Lilly (NYSE: LLY). Avid used 152 participants to perform brain scans and autopsies (upon...

Eli Lilly and Company (LLY) and partner Acrux recently announced good news in the form of US Food and Drug Administration (FDA) approval for Axiron. The FDA approved Axiron for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Eli Lilly acquired exclusive worldwide rights to commercialize Axiron earlier [...]

Having worked with the Generex team in the fledgling stage of Generex Oral-lyn development while at Eli Lilly, I believed then that the product had the potential to become a first-in-class therapeutic insulin treatment even though the companies ultimately headed in different directions as is often the case with early [...]

Last week, I presented my dividend stock analysis template. I will play around with it for a few weeks but I had already used the original template to analyze Eli Lilly LLY. The Company Stock Description: Founded in 1876, Eli Lilly is now the 10th largest pharmaceutical company in the world. If you don’t know [...]

The market staged a strong rally over the past week, but not every sector has followed suit. And while major pharmaceutical stocks aren't typically thought of as high-yielding plays, the segment's underperformance has taken down prices of some names in the space, giving dividend-focused investors a better opportunity to capture high yields. As a whole, the [...]

(RTTNews) - The Hyderabad-based Aurobindo Pharma Ltd. announced that the company had received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delay-Release capsules are the generic equivalent of Eli Lilly and Company's Cymbalta Delayed-Release capsules 20mg (base), 30mg (base) and 60mg [...]

Hapoalim Securities is out with a research report this afternoon, where it reiterates its Sell rating on Eli Lilly & Co. (NYSE: LLY); it has a $30 price target on the stock. The analysts cited the company's recently announcement earnings report, saying, “As a result of better-than-expected operating costs and lower-than-expected revenues in 3Q10, we are decreasing our 2010-2014 operating cost and revenue estimates. For 2010, lower costs more than offset lower revenues, which increases our...

Goldman Sachs has issued a research report on Eli Lilly & Company (NYSE: LLY) after the company received a complete response letter for Bydureon, as the FDA has changed its mind on the approval of the drug and has requested more thorough research to be conducted on renally impaired patients with exposures of exenatide. In the report, Goldman Sachs writes “the issue is not specific to Bydureon or exenatide, but rather the companies' understanding is that this tQT study will be required...

Coca-Cola FEMSA SAB de CV (NYSE: KOF) was downgraded by Deutsche Bank from "hold" to "sell." KOF's shares closed at $80.55 yesterday. KOF's quarterly sales moved up 4.11% y/y. Citigroup downgraded Eli Lilly & Co (NYSE: LLY) from "buy" to "hold." LLY's stock closed at $37.45 yesterday. Eli Lilly's earnings are likely to drop by 5.93% in the next 5 years. JP Morgan downgraded Illinois Tool Works Inc (NYSE: ITW) from "overweight" to "neutral." ITW's shares closed at $46.48 yesterday....

In a report on core product trends for the week ending 10/1/10, Citigroup reports that Eli Lilly and Company's (NYSE: LLY) Cymbalta posted weekly NRx/TRx of 156,732(-1%)/ 368,914 (-1%);9.9%(-3bp) TRx depression market share. Rolling 4wk/12wk NRx growth rates were +0%/+1%; TRx rates were +1%/+1%.LLY took an 8% PI on 9/3/10, w/ 30/60mg flat priced at $4.61/day. “Lilly recently traded at ~8x our 2011 EPS estimate, which is below where we peg Lilly's 15-year average forward multiple, at 20x...

Eli Lilly’s (LLY) oncology pipeline suffered a setback recently with the company reporting disappointing results on Alimta from a phase III study. Data, presented at the annual meeting of the European Society for Medical Oncology (ESMO), showed that Alimta failed to achieve its primary endpoint in a phase III study that was being conducted in [...]

Citigroup has issued a research report for Eli Lilly (NYSE: LLY) reporting on trends for the week ending 10/1/2010. In the report, Citigroup writes "We rate Lilly High Risk, largely because of a period of considerable generic risk in 2011-13 that is mitigated in part by a solid drug pipeline. Specifically, the company faces a number of patent expirations in 2011-13 (Zyprexa, Evista, Gemzar, Cymbalta), which in aggregate a significant portion of Lilly's earnings. The company also faces a...

Below are the top healthcare stocks on the NYSE in terms of dividend yield. Eli Lilly and Company (NYSE: LLY) has a dividend yield of 5.30%. LLY's shares closed at $37.22 yesterday. Bristol-Myers Squibb Company (NYSE: BMY) has a dividend yield of 4.70%. BMY's shares closed at $27.36 yesterday. GlaxoSmithKline Plc (NYSE: GSK) has a dividend yield of 4.40%. GSK's shares closed at $41.44 yesterday. Pfizer Inc (NYSE: PFE) has a dividend yield of 4.10%. PFE's shares closed at $17.38...

A head and neck cancer drug Eli Lilly & Co. (NYSE: LLY) has failed a Phase 3 trial, and shares are down almost 1% in pre-market trading. According to a report from the Wall Street Journal, the drug did not meet its expectations for the 795 patients who were part of the study. A similar drug from Amgen, Inc. (NASDAQ: AMGN) also recently failed a Phase 3 trial, and there has been speculation that either of these large pharmaceutical companies could acquire CEL-SCI Corporation (NYSE: CVM)...

Citigroup has published a research report for Eli Lilly (NYSE: LLY) reporting on core product trends for the week ending on 9/24. In the report, Citigroup writes " Effient: 2.7% NRx's of Plavix Market; We Assume 2010 US Sales of $100M. Effient weekly NRx/TRx of 5,691 (+3% seq.)/13,578(+2%) vs.Plavix at 203,096 (+3%) /665,533(+1%). Effient is flat priced at $5.40/day (at a modest premium to Plavix [$5.38/day] after BMY/SNY took a 4.9% price increase in Sept '10).  Livalo: Quarter to...

Eli Lilly and Company (NYSE: LLY) today announced that pharmaceutical industry veteran Jeffrey A. Winton has been named vice president of communications. Winton will assume this role on October 11, and will become a member of the Eli Lilly and Company Global Corporate Affairs Leadership Team. Winton most recently served as co-owner and managing partner of West Mill Consulting in Long Valley, New Jersey. In this capacity, he also served as interim head, communications and public relations...

J.P.Morgan Chase & Co. rates Eli Lilly & Company (NYSE: LLY) at Underweight with a $36 price target, after meeting with company management recently. In the research note, J.P. Morgan writes, "We recently met with several members of Lilly's management team in Indianapolis and wanted to share our takeaways from the discussions. The meeting highlighted some of Lilly's key pipeline opportunities as well as the efforts the company is making to prepare itself for its upcoming patent cycle....

Eli Lilly’s (LLY) Cymbalta will be coming up for review before the US Food and Drug Administration’s (FDA) Anesthetic and Life Support Drugs Advisory Committee on Aug 19, 2010. Eli Lilly is seeking to expand Cymbalta’s label so that the product can be used for the management of chronic low back pain and treatment of [...]

Publisher Brian Hicks brings readers the latest developments in the fight against Alzheimer's... and a game-changing stock that's up 50% for the year.

When investors think of high yielding sectors, typically the healthcare and major drugs segment doesn't come to mind. However, with broad benchmarks still off nearly -4% over the last week, several names in the big pharma space have gone along for the ride, giving investors the opportunity to capture high yields. Given their nature [...]

Eli Lilly and Company (LLY) recently announced that it intends to acquire privately held biotech company Alnara Pharmaceuticals Inc. Alnara specializes in the development of protein therapeutics for the treatment of metabolic diseases. The financial terms of the deal were not disclosed. With this acquisition, Eli Lilly is looking to enter the enzyme replacement therapy market, [...]

Following the release of first quarter results on April 19, 2010, almost all the analysts covering Eli Lilly (LLY) have made downward revisions to their 2010 and 2011 annual estimates. A major part of the reduction was due to the impact of US healthcare reform, which is expected to affect the company’s earnings significantly. Long-term performance [...]

Recently, Eli Lilly (LLY) presented data from a mid-stage study of one of its pipeline candidates, tasisulam. The drug is being studied in a phase II trial as a second-line treatment in patients with metastatic melanoma. While overall response rate was the primary objective of the trial, there were two secondary objectives – progression-free survival and [...]

Eli Lilly (LLY) reported first quarter earnings per share of $1.18, a couple of cents below the year-ago earnings of $1.20, but above the Zacks Consensus Estimate of $1.11. Results included a 12-cent impact due to the US health care reform. Excluding this impact, earnings would have increased 4% from the year ago period. Revenues recorded [...]

My allocation towards healthcare stocks has been hurting lately and I haven't been able to decide in which direction I wanted to go.  That changed after I read an article in Barron's yesterday that listed a handful of dividend paying stocks that have yields greater than their five year debt.  Eli Lilly & Co. (LLY) [...]